Standout Papers

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: ... 2021 2026 2022 2024203
  1. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study (2021)
    Martin Hutchings, Rogier Mous et al. The Lancet

Citation Impact

56 standout
Sub-graph 1 of 20

Citing Papers

The interaction of innate immune and adaptive immune system
2024 Standout
The present and future of bispecific antibodies for cancer therapy
2024 Standout
5 intermediate papers

Works of Tommy Li being referenced

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
2021 Standout

Author Peers

Author Oncology RNMI Immunology PFM Last Decade Papers Cites
Tommy Li 326 100 76 182 15 372
Yaqi Xing 1 4 25 12 643
Sarojini Johri 5 4 13 314
Robert Fong 2 3 1 14 395
P.J. Valette 73 18 4 24 334
Xiaoquan Cheng 76 985

All Works

Loading papers...

Rankless by CCL
2026